shanxi Xiyue Pharmaceutical Co., Ltd.

Shaanxi Xiyue Pharmaceutical Co., Ltd. (hereinafter referred to as “Xiyue Pharma”) is a professional manufacturing enterprise mainly engaged in R&D and production of APIs. Xiyue Pharma was founded in 1968. Its predecessor was the Northwest Second Synthetic Pharmaceutical Factory, a state-owned joint-venture with Hongkong Tianma Trading Company, which was affiliated to the Ministry of Chemical Industry and was the largest API production base in Western China. In Nov, 2008, Xiyue Pharma was wholly-owned acquired by Shaanxi Haichen Yunhe Pharmaceutical Technology Co., Ltd and was transformed into an efficient, professional private high-tech enterprise, and a modernized pharmaceutical enterprise with pharmaceutical R&D, production and sales intergrated. The company is headquartered in Xi'an, the start of the world-known Silk Road, and the ancient capital of China. It has 50 million registered capital and now has two manufacturing factories, which are located in Huayin Biomedical Industrial Park and Baoji Fufeng Science and Technology Industrial Park, covering a total area of more than 200,000 square meters. Xiyue Pharma currently has 113 approval numbers, including 23 API approvals and 90 preparation approvals. The products cover a wide range of cardiovascular and cerebrovascular, nervous system, antipyretic and analgesic, digestive fields and so on. The company has established and perfected the quality management system in strict accordance with the new national GMP standards. It has more than 10 production lines of APIs, tablets, capsules and granules, etc. Its production scale, technical level, brand influence and economic benefits rank among the top in the domestic industry. The company's products are mainly sold in domestic and are widely used in overseas markets. The domestic market share of products like Nifedipine and Aceglutamide, etc. is leading over 80%, and Diclofenac Sodium and Nifedipine have been sold to countries such as Argentina, Pakistan, India and so on. The company also undertakes international API contract processing business and has established strategic partnerships with many famous domestic and foreign companies, such as the Shanghai Pharmaceuticals Holding Co. Ltd. (“SPH” Group), China National Pharmaceutical Group Co., Ltd. (Sinopharm) and Buchang Pharmaceuticals (Buchang Pharma). Xiyue Pharma has more than 300 employees, including more than 100 professional and technical personnels, and more than 30 senior and intermediate researchers. The company attaches great importance to the development of new products, invests a large amount of funds each year for research and development, and has established a pharmaceutical research institute by a number of doctors and masters. It has maintained a long-term close cooperation with many domestic research institutions in production and research, to ensure the products’ technology innovation and new products’ launch, and to meet the diverse needs of customers at home and abroad. Xiyue Pharma also pays great attention to the environmental protection and has passed various inspections of the national environmental assessment of the pharmaceutical industry. The production strictly follows the EHS policy, strengthens the prevention principle of the whole process, and eliminates any environmental pollution and social hazard accidents, to ensure a safe, efficient and consistent supply of products. The Company adhering to the people-oriented, care for health corporate philosophy, is committed to making Xiyue Pharma an internationally renowned, domestic leading API pharmaceutical manufacturing enterprise.